CN1498105A - 含有类维生素a受体配体和选择的细胞毒性剂的用于治疗癌症的协同联合体系 - Google Patents

含有类维生素a受体配体和选择的细胞毒性剂的用于治疗癌症的协同联合体系 Download PDF

Info

Publication number
CN1498105A
CN1498105A CNA028070011A CN02807001A CN1498105A CN 1498105 A CN1498105 A CN 1498105A CN A028070011 A CNA028070011 A CN A028070011A CN 02807001 A CN02807001 A CN 02807001A CN 1498105 A CN1498105 A CN 1498105A
Authority
CN
China
Prior art keywords
rar
cytotoxic agent
formula
selected cytotoxic
pan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028070011A
Other languages
English (en)
Chinese (zh)
Inventor
V��S������-����
V·S·维瓦特－汉纳
M·V·洛朗齐
M·M·弋阿拉迪斯
F·C·祖西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN1498105A publication Critical patent/CN1498105A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA028070011A 2001-03-22 2002-03-22 含有类维生素a受体配体和选择的细胞毒性剂的用于治疗癌症的协同联合体系 Pending CN1498105A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27775401P 2001-03-22 2001-03-22
US60/277,754 2001-03-22

Publications (1)

Publication Number Publication Date
CN1498105A true CN1498105A (zh) 2004-05-19

Family

ID=23062213

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028070011A Pending CN1498105A (zh) 2001-03-22 2002-03-22 含有类维生素a受体配体和选择的细胞毒性剂的用于治疗癌症的协同联合体系

Country Status (15)

Country Link
EP (1) EP1383491A2 (https=)
JP (1) JP2004528316A (https=)
KR (1) KR20030086314A (https=)
CN (1) CN1498105A (https=)
BR (1) BR0207681A (https=)
CA (1) CA2441335A1 (https=)
CZ (1) CZ20032540A3 (https=)
DE (1) DE02733871T1 (https=)
ES (1) ES2214985T1 (https=)
HU (1) HUP0400255A2 (https=)
IL (1) IL157358A0 (https=)
MX (1) MXPA03008403A (https=)
PL (1) PL368946A1 (https=)
TR (1) TR200400812T3 (https=)
WO (1) WO2002078620A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113038B2 (ja) * 2006-03-23 2013-01-09 テムリック株式会社 癌治療用キットおよび癌治療用医薬組成物

Also Published As

Publication number Publication date
PL368946A1 (pl) 2005-04-04
IL157358A0 (en) 2004-02-19
BR0207681A (pt) 2004-07-27
HUP0400255A2 (hu) 2004-08-30
KR20030086314A (ko) 2003-11-07
DE02733871T1 (de) 2004-08-26
TR200400812T3 (tr) 2004-07-21
ES2214985T1 (es) 2004-10-01
JP2004528316A (ja) 2004-09-16
WO2002078620A2 (en) 2002-10-10
CA2441335A1 (en) 2002-10-10
CZ20032540A3 (cs) 2004-05-12
WO2002078620A3 (en) 2003-04-17
MXPA03008403A (es) 2004-01-29
EP1383491A2 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
US6130230A (en) Therapeutic combinations of RAR antagonists and RXR agonists and use thereof
Theodosiou et al. From carrot to clinic: an overview of the retinoic acid signaling pathway
Campbell et al. Expression of retinoic acid receptor-β sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog
WO1998008546A9 (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
JP2014522844A (ja) 白血病を治療するための組成物、方法及びキット
Badr 15-Lipoxygenase products as leukotriene antagonists: therapeutic potential in glomerulonephritis.
Nagpal et al. Retinoids as anti-cancer agents
AU701790B2 (en) Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}
JP2006117691A (ja) グラム陰性感染に対する細胞防御を促進するためのリポキシンアナログの使用
JP4737931B2 (ja) 医薬品の製造におけるヒドロキシオレイン酸及び類似化合物の使用
Sun et al. Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids
Traves et al. Selective activation of liver X receptors by acanthoic acid-related diterpenes
Schaier et al. Isotretinoin alleviates renal damage in rat chronic glomerulonephritis
Garcia-Bates et al. Role of peroxisome proliferator‐activated receptor gamma and its ligands in the treatment of hematological malignancies
AU773928B2 (en) Compositions and methods for treatment of hyperproliferative diseases
CN1498105A (zh) 含有类维生素a受体配体和选择的细胞毒性剂的用于治疗癌症的协同联合体系
US20040122080A1 (en) Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
US6624154B1 (en) Compositions and methods for treatment of hyperproliferative diseases
Li et al. Virulizin®, a novel immunotherapy agent, stimulates TNFα expression in monocytes/macrophages in vitro and in vivo
JP2006526662A (ja) 過増殖性細胞疾患を治療する方法
AU2002305072A1 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
Douer Transcription therapy for acute promyelocytic leukaemia
WO2011046200A1 (ja) 分化誘導因子又はその類縁体を含有する抗炎症剤
JP2005053780A (ja) 核内レセプタースーパーファミリーの新規リガンド、その製法及び用途
Pastwinska et al. BBA-Reviews on Cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication